PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Novozymes Biopharma Announces New Development in Animal-Free Cell Culture Supplements - Novozymes Biopharma announces new development in animal-free cell culture supplements at BioProcess International Conference and Exhibition 2008
Novozymes Biopharma Announces New Development in Animal-Free Cell Culture Supplements

 

NewswireToday - /newswire/ - Nottingham, United Kingdom, 2008/09/18 - Novozymes Biopharma announces new development in animal-free cell culture supplements at BioProcess International Conference and Exhibition 2008.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Novozymes Biopharma, part of Novozymes, world leader in bioinnovation, announces a new development in animal-free supplements for industrial cell culture on booth #219 at BioProcess International Conference and Exhibition, 23-26 September 2008, Disneyland Hotel, Anaheim, CA, USA.

Novozymes Biopharma, specialists in large scale recombinant protein production for the biopharmaceutical industry, unveils the first product under the CellPrime brand. Novozymes' Transferrin recombinant supplement is now commercially ready in scalable manufacturing quantities for consistency of supply. Designed to reduce risk and ease regulatory concerns for biopharmaceutical manufacturers, this new advance will improve the consistency and productivity of customers' industrial cell culture process.
Manufactured by Novozymes Biopharma, Transferrin is sold exclusively through Millipore Corporation as part of the CellPrime alliance announced in December 2007.

Novozymes Biopharma will also exhibit its two key product lines, Recombumin and LONGR3 IGF-I, on booth #219. Recombumin is a yeast derived recombinant human albumin, which has a structure identical to human serum albumin (HSA).
It is the world's first and only animal-free recombinant human albumin approved for use in the manufacture of human therapeutics. LONGR3 IGF-I is an analogue of human insulin-like growth factor I (IGF-I) specifically engineered by Novozymes Biopharma for use in industrial cell culture. LONGR3 IGF-I provides improved performance and a consistent, compliant and animal-free alternative to recombinant insulin.

Novozymes Biopharma's portfolio includes biopharmaceutical technologies and services, contract manufacturing of pharmaceutical grade biological APIs, and services such as cell banking, technology transfer and process development.

Novozymes Biopharma demonstrates in-depth expertise during the technical conference with:
. A poster display on "Advances in animal free media supplements for optimal cell culture performance," presented by Sally Grosvenor, Senior Scientist and Scientific Communications Manager, Novozymes Biopharma AU Ltd. in the poster area, Disneyland Hotel, Anaheim.
. A workshop, entitled "Cell Culture and Processing Track" hosted by Sally Grosvenor, on 25th September 2008 at Magic Kingdom 2 and 3 at 12-12.30pm, will discuss the ability of two key serum proteins, Transferrin and IGF-I, to stimulate cell growth and productivity.
. Geoff Francis, Chief Scientist, Novozymes Biopharma AU Ltd is moderator of the Novozymes sponsored Panel Discussion "Cell Engineering the Future - A Role for Media Innovation" 12.30pm on 25th September 2008.

To learn more about Novozymes Biopharma's portfolio of products, please visit booth #219 at BioProcess International Conference and Exhibition 2008.

About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources.

With over 700 products used in 130 countries, Novozymes' bioinnovations improve industrial performance and safeguard the world's resources by offering superior and sustainable solutions for tomorrow's ever-changing marketplace.

Novozymes' natural solutions enhance and promote everything from removing trans-fats in food, to advancing biofuels to power the world tomorrow. Our never-ending exploration of nature's potential is evidenced by over 4,500 patents, showing what is possible when nature and technology join forces.

Our 4,500+ employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow.

To arrange a booth meeting with Novozymes Biopharma at BioProcess International 2008 please contact Fiona Robinson, The Scott Partnership on fer[.]scottpr.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Novozymes Biopharma Announces New Development in Animal-Free Cell Culture Supplements

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Fiona Robinson 
+44 115 9551209 syke[.]novozymes.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From The Scott Partnership / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)